Despite its specificity, the FTA-ABS test has limitations. One major limitation is that it cannot distinguish between active and past infections since it remains positive for life. This means that it cannot be used to monitor treatment efficacy or detect reinfection. Additionally, false positives can occur in some cases, such as in patients with autoimmune diseases, and therefore clinical correlation is necessary.
